News | January 11, 2023
Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
Passengers arriving from 6 high-risk countries are now mandatorily required to upload their negative RT-PCR test
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Subscribe To Our Newsletter & Stay Updated
